Regional Health Properties Valuation

Q: What is the Fair Price of RHE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

RHE ($1.52) is trading below our estimate of [[fair value]] ($1.85)

Is RHE undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of RHE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: RHE ($1.52) is trading below our estimate of fair value ($1.85)

Significantly Below Fair Value: RHE is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for RHE?

Key metric: As RHE is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for RHE. This is calculated by dividing RHE's market cap by their current revenue.
What is RHE's PS Ratio?
PS Ratio	0.2x
Sales	US$15.75m
Market Cap	US$2.74m

RHE key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	4.7x
Enterprise Value/EBITDA	40.6x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does RHE's PS Ratio compare to its peers?

The above table shows the PS ratio for RHE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	2.1x
SSY SunLink Health Systems	0.2x	n/a	US$5.8m
GRST Ethema Health	0.7x	n/a	US$5.0m
TOI Oncology Institute	0.03x	n/a	US$13.6m
IMTH Innovative MedTech	7.6x	n/a	US$13.4m
RHE Regional Health Properties	0.2x	n/a	US$2.7m

Price-To-Sales vs Peers: RHE is good value based on its Price-To-Sales Ratio (0.2x) compared to the peer average (2.1x).

Price to Sales Ratio vs Industry

How does RHE's PS Ratio compare vs other companies in the US Healthcare Industry?

31 Companies	Price / Sales	Estimated Growth	Market Cap
Industry Avg.	1.0x	6.6%
RHE Regional Health Properties	0.2x	n/a	US$2.74m
MCK McKesson	0.2x	8.1%	US$78.15b
CVS CVS Health	0.2x	4.6%	US$70.18b

31 Companies		Estimated Growth	Market Cap
Industry Avg.	1.0x	20.8%
RHE Regional Health Properties	0.2x	n/a	US$2.74m

No more companies

Price-To-Sales vs Industry: RHE is good value based on its Price-To-Sales Ratio (0.2x) compared to the US Healthcare industry average (1x).

Price to Sales Ratio vs Fair Ratio

What is RHE's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

RHE PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.2x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate RHE's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

CVS Health

US$70.2b

Provides health solutions in the United States.

CVS

US$56.83

4.7%

-17.8%

Centene

US$29.2b

Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.

CNC

US$59.10

1.8%

-20.4%

Elevance Health

US$91.4b

Operates as a health benefits company in the United States.

ELV

US$397.48

-3.3%

-17.2%